Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNKS2 | Q9H2K2 | 11/20 | 0.60 |
| ▸ | TNKS | O95271 | 10/20 | 0.60 |
| ▸ | PARP2 | Q9UGN5 | 6/20 | 0.60 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.59 |
| ▸ | PARP1 | P09874 | 5/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30186048 | 0.87 | TNKS (0.59) | TNKS2TNKSPARP2PARP14PARP1 | |
| SCHEMBL6930649 | 0.87 | TNKS (0.59) | TNKS2TNKSPARP2PARP14PARP1 | |
| SCHEMBL19104690 | 0.85 | TNKS (0.56) | TNKS2TNKSPARP2PARP14PARP1 | |
| SCHEMBL3980805 | 0.80 | TNKS (0.65) | TNKS2TNKSPARP2PARP14PARP1 | |
| SCHEMBL21127496 | 0.80 | PARP14 (0.60) | TNKS2TNKSPARP2PARP14PARP1 | |
| SCHEMBL17298080 | 0.80 | PARP1 (0.66) | TNKS2TNKSPARP2PARP14PARP1 | |
| SCHEMBL1387202 | 0.80 | TNKS2 (0.66) | TNKS2TNKSPARP2PARP14PARP1 | |
| SCHEMBL3423314 | 0.79 | TNKS (0.67) | TNKS2TNKSPARP2PARP14PARP1 | |
| SCHEMBL15857995 | 0.79 | TNKS (0.67) | TNKS2TNKSPARP2PARP14PARP1 | |
| SCHEMBL8438092 | 0.79 | PARP1 (0.65) | TNKS2TNKSPARP2PARP14PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170197958-A1 | AGONISTS OF THE APELIN RECEPTOR AND METHODS OF USE THEREOF | Sanford Burnham Prebys Medical Discovery Institute | 2017-07-13 | — | — | US | disclosed |
| WO-2015184011-A2 | AGONISTS OF THE APELIN RECEPTOR AND METHODS OF USE THEREOF | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2015-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170197958-A1 | AGONISTS OF THE APELIN RECEPTOR AND METHODS OF USE THEREOF | APLNR, AGTR1, AGTR2 | TNKS2 4481/4885TNKS 4665/4885PARP2 4519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.